Back in April, Springer retracted a record number 107 papers from Tumor Biology after uncovering evidence they were subject to fake peer reviews. But it appears that the Tumor Biology sweep was only part of the story.
During the Tumor Biology investigation, Springer found evidence that the “peer review process was compromised” in a dozen papers on brain cancer published in another journal. The 12 Molecular Neurobiology retractions have trickled in over the past year or so, published before and after the Tumor Biology sweep.
A spokesperson at Springer confirmed that the 12 retracted papers in Molecular Neurobiology were related to the Tumor Biology retractions for fake peer review: Continue reading Springer purge of fake reviews takes down 10+ more neuroscience papers
Authors have admitted to using material from another lab for their paper on neuroblastoma.
A spokesperson for Springer told us that the theft came to light when:
The scientists, from whom the data originated, contacted the journal.
The editor in chief of the journal investigated the case, the spokesperson told us, and then issued this retraction notice:
Continue reading Cancer researchers: We took data from another lab
This is officially becoming a trend: Springer is pulling another 64 articles from 10 journals after finding evidence of faked peer reviews, bringing the total number of retractions from the phenomenon north of 230.
Given that there have been about 1,500 papers retracted overall since 2012, when we first reported on the phenomenon, faked reviews have been responsible for about 15% of all retractions in the past three years.
This isn’t the first time Springer has faced the issue. As owner of the BioMed Central journals, it issued 43 retractions for faked reviews earlier this year.
In a statement, the publisher explains how the latest round of retractions came to light: Continue reading 64 more papers retracted for fake reviews, this time from Springer journals